BMS 300 mg 3622 (Reyataz 300 mg)
Generic Name: atazanavir
Pill imprint BMS 300 mg 3622 has been identified as Reyataz 300 mg.
Reyataz is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class protease inhibitors. There is no proven risk in humans during pregnancy. Reyataz 300 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- atazanavir
- Imprint:
- BMS 300 mg 3622
- Strength:
- 300 mg
- Color:
- Red / Blue
- Size:
- 23.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Protease inhibitors
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Bristol-Myers Squibb
- National Drug Code (NDC):
- 00003-3622
- Inactive Ingredients:
- crospovidone
lactose monohydrate
magnesium stearate
gelatin
FD&C Blue No. 2
titanium dioxide
ferric oxide red
ferric oxide yellow
isopropyl alcohol
ammonia
propylene glycol
butyl alcohol
alcohol
ferrosoferric oxide
shellac
| NDC Code | Manufacturer / Repackager |
|---|---|
| 54569-5864 | A-S Medication Solutions, LLC (repackager) |
| 54868-5838 | Physicians Total Care Inc (repackager) |
| 35356-0114 | Lake Erie Medical and Surgical Supply (repackager) |
| 68258-1985 | Dispensing Solutions Inc. (repackager) |
Note: Inactive ingredients may vary.
More about Reyataz (atazanavir)
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
